November 21, 2018 Regulatory LIDDS adds two major university clinics in Lithuania to speed up enrollment in ongoing Phase IIb study
November 16, 2018 Non Regulatory LIDDS presence at BIO-Europe 2018 to focus on NanoZolid’s broad drug formulation capability
November 1, 2018 Non Regulatory LIDDS presence at BIO-Europe 2018 to focus on NanoZolid’s broad drug formulation capability
July 30, 2018 Regulatory New STING study opens up multi-billion dollar cancer immunotherapy market for LIDDS unique NanoZolid® technology
June 25, 2018 Non Regulatory LIDDS’ NanoZolid® technology recognized through publication of scientific article in Journal of Drug Delivery Science and Technolog
June 7, 2018 Regulatory LIDDS: Major European Investment Funds invest 21,7 MSEK in a direct share issue
May 16, 2018 Regulatory LIDDS signs license agreement for prostate cancer drug Liproca® Depot with major Chinese pharma company
May 15, 2018 Regulatory LIDDS broadens the scope of its technology platform by verifying NanoZolid® as subcutaneous depot for systemic delivery
March 15, 2018 Regulatory LIDDS: NanoZolid® with cutting edge STING agonist becomes a key project for LIDDS in immuno-oncology field
February 8, 2018 Regulatory LIDDS: Liproca® Depot effects on prostate cancer to be presented at the Paris Symposium for Magnetic Resonance in Medicine
January 10, 2018 Regulatory LIDDS: NanoZolid® with immune-stimulating agent confirms efficacy in an additional cancer model